Table 1. Clinical, laboratorial and radiological characteristics of the study population at diagnosis and just before pegvisomant treatment (PEGV-OFF).
| Total (N = 109) | Women (N = 61) | Men (N = 48) | |
|---|---|---|---|
| At diagnosis | |||
| Age (yrs) | 34 (12 – 82) | 37 (12 – 82) | 34 (12 – 63) |
| Micro/Macroadenoma (n) | 5/103 | 2/58 | 3/45 |
| GH (µg/L) | 24.2 (0.9 – 1136) | 20.8 (3.0 – 680) | 26.0 (0.9 – 1136) |
| IGF-I (ng/mL) | 1053 (396 – 2376) | 910 (396 – 2376) | 1190 (409 – 2320) |
| IGF-I (%ULN) | 327 (120 – 756) | 313 (129 – 672) | 349 (120 – 756) |
| At PEGV-OFF | |||
| Previous surgery (%) | 97 (89) | 53 (87) | 44 (92) |
| Previous radiotherapy (%) | 37 (34) | 21 (34) | 16 (33) |
| Previous SRL (%) | 108 (99) | 60 (98) | 48 (100) |
| Previous cabergoline (%) | 73 (67) | 39 (64) | 34 (71) |
| Pre-diabetes/Diabetes (%) | 53 (49) | 33 (54) | 20 (42) |
| Tumour remnant (%) | 77 (71) | 39 (64) | 38 (79) |
| GH (µg/L) | 4.3 (0.71 – 209) | 4.0 (0.72 – 209) | 4.7 (0.71 – 101) |
| IGF-I (ng/mL) | 613 (262 – 1503) | 569 (275 – 1503) | 650 (262 – 1312) |
| IGF-I (%ULN) | 209 (99 – 637) | 194 (99 – 637) | 220 (100 – 596) |
Values are shown as median (min – max); %ULN: % upper limit of normal; SRL: somatostatin receptor ligands; no significant differences between men and women were observed.